NET Cancer Day
Dec 12 2013
The South Australian Cancer Pathway for Gastroenteropancreatic NETs Launched on November 13th at Major Oncology Meeting in Australia (COSA ASM). The Unicorn Foundation is proud to announce the launch of the South Australian Gastroenteropancreatic NETs (SA GEP NET) Cancer Pathway during the Clinical Oncology Society meeting by the Hon Jack Snelling MP, South Australian Minister for Health and Aging.
The SA GEP NET pathway was supported by the Unicorn Foundation and involved a wide variety of health professionals, NET specialists and consumers.The Unicorn Foundation is particularly thankful for the efforts of Koli Ali (NETs project nurse), Prof Tim Price and Prof Dorothy Keefe for their enthusiasm and input into this important clinical pathway. Click here to view this pathway.
Sunitinib (Sutent) is Now available on the Pharmaceutical Benefits Scheme for Australian Pancreatic Neuroendocrine Tumor Patients
After many months of lobbying and advocating for equitable access to sunitinib (Sutent), Dr. John Leyden, Chairman of the Unicorn Foundation, is happy to announce that the Pharmaceutical Benefits Advisory Board has finally listed the drug for the treatment of metastatic pancreatic neuroendocrine tumor patients. This is a significant result for all Australian patients with pancreatic NETs as previously the costs of this drug have been prohibitive and remained out of reach of nearly all patients. The equitable and timely access to treatments for neuroendocrine cancer patients remains an important focus for the International Neuroendocrine Cancer Alliance (INCA) and its member groups.